Apricus Bio (APRI) Files Response with Swissmedic Related to Vitaros MAA; May Trigger Pre-Decision

June 14, 2012 9:38 AM EDT Send to a Friend
Get Alerts APRI Hot Sheet
Trade APRI Now!
Apricus Biosciences, Inc. (Nasdaq: APRI) announced that the Company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application previously filed for Vitaros, the Company's lead product candidate for the treatment of erectile dysfunction in Switzerland.

The filing of the Apricus Bio response triggers a 90-day review process, after which if found acceptable, may then trigger a pre-decision by Swissmedic for the approval of Vitaros for ED in that country. Following a subsequent approval decision and any required Company responses, Apricus Bio would then be required to supply Swissmedic with the final labeling and pricing information of Vitaros, which could take an additional 90 days for review and acceptance before that product can be marketed in Switzerland.

Apricus is currently in discussions with multiple potential commercial partners for VitarosĀ® for ED in Switzerland.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment